REG - Redx Pharma plc - Collaboration with the Garvan Institute

Redx PharmaAnnouncement

05/04/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220405:nRSE2241Ha&default-theme=true

RNS Number : 2241H  Redx Pharma plc  05 April 2022

REDX PHARMA PLC

("Redx" or "the Company")

 

Redx Announces Collaboration with the Garvan Institute of Medical Research

 

Expanded collaboration to investigate novel therapeutic targets in
cancer-associated fibrosis

 

Alderley Park, 5 April 2022, Redx (AIM: REDX), the clinical-stage
biotechnology company focused on discovering and developing novel, small
molecule, highly targeted therapeutics for the treatment of cancer and
fibrotic disease, today announces a collaboration with the Garvan Institute of
Medical Research ("the Garvan"), a premier Australian medical research
institute, which expands on preclinical work already underway.

 

The collaboration aims to better understand treatments that could lead to
increased patient survival in currently very poorly treated highly fibrotic
cancers, such as pancreatic cancer.  Through this collaboration, Redx and the
Garvan will develop an enhanced understanding of cancer-associated fibrosis
through detailed scientific studies utilising patient-derived tumour tissue
grown in mice, which is thereby able to mimic human disease as closely as
possible. The research will bring together the Garvan's research capabilities
and leading preclinical cancer models with Redx's proprietary molecules in
development for novel targets potentially implicated in cancer-associated
fibrosis, such as Porcupine, ROCK2 and Discoidin Domain Receptors (DDR).

 

The Garvan is globally renowned for its interest in pancreatic cancer and is
currently leading the MoST-P clinical trial programme in conjunction with the
University of New South Wales (UNSW) Sydney. The programme provides cancer
patients with access to targeted therapies matched to the genomic and/or the
fibrotic signature of their tumour or tumour environment. RXC004, a Porcupine
inhibitor and Redx's lead oncology product candidate, is being tested against
RNF43 mutant pancreatic cancer and preclinical work is ongoing to determine if
the patient population may be expanded beyond RNF43 loss of function patients
to include a wider fibrotic signature in pancreatic cancer.

 

Initial data on proprietary Redx molecules in patient-derived preclinical
cancer models from the collaboration are expected to be presented by Professor
Marina Pajic, Strategic Program Lead for Precision Medicine for Cancer at the
Garvan, at the Extracellular Matrix (ECM) Congress, which will take place in
Copenhagen, Denmark on 23-25 June 2022. Further data on patient-derived
pancreatic cancer models, expected to be published later in 2022, will enhance
insight into Wnt-ligand driven tumours, the target patient group for RXC004,
which is currently in Phase 2 development for the treatment of genetically
selected pancreatic cancer, genetically selected metastatic colorectal cancer
and unselected biliary cancer.

 

Professor Marina Pajic, Strategic Program Lead for Precision Medicine for
Cancer at the Garvan Institute, commented: "We are very pleased to be
expanding our partnership with Redx and to be benefitting from its medicinal
chemistry expertise to work on a range of molecules under development for
these novel targets to discover new therapeutic options for patients with
fibrotic cancers, a core area of our research focus."

 

Dr Caroline Phillips, Head of Oncology at Redx, added: "We are thrilled to be
combining the Garvan's world-leading research in our key areas of focus,
fibrotic cancers and cancer associated fibrosis, to explore the potential of
Redx's molecules and novel targets in this leading collaboration. With our
focus on fibrosis and oncology and our world-class medicinal chemistry, we are
able to contribute a range of molecules from Redx's differentiated pipeline to
further research and develop new targeted therapies for these hard-to-treat
conditions."

 For further information, please contact:

 Redx Pharma Plc                                                         T: +44 (0)1625 469 918

 ir@redxpharma.com (mailto:ir@redxpharma.com)

 UK Headquarters

 Lisa Anson, Chief Executive Officer

 US Office

 Peter Collum, Chief Financial Officer

 SPARK Advisory Partners (Nominated Adviser)                             T: +44 (0)203 368 3550
 Matt Davis/ Adam Dawes

 WG Partners LLP (Joint Broker)                                          T: +44 (0)203 705 9330
 Claes Spång/ Satheesh Nadarajah/ David Wilson

 Panmure Gordon (UK) Limited (Joint Broker)                              T: +44 (0)207 886 2500
 Rupert Dearden/ Freddy Crossley/ Emma Earl

 FTI Consulting                                                          T: +44 (0)203 727 1000
 Simon Conway/ Ciara Martin

 

About Redx Pharma Plc

Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on
the discovery and development of novel, small molecule, highly targeted
therapeutics for the treatment of cancer and fibrotic diseases, aiming
initially to progress them to clinical proof of concept before evaluating
options for further development and potential value creation. Redx's lead
oncology product candidate, the Porcupine inhibitor RXC004, commenced a Phase
2 programme in November 2021. The Company's selective ROCK2 inhibitor product
candidate, RXC007, is in development for idiopathic pulmonary fibrosis and
commenced a Phase 1 clinical trial in June 2021. Encouraging safety and
pharmacokinetic data has been reported, and a Phase 2 clinical programme is
confirmed to start in 2022. Redx's third drug candidate, RXC008, a
GI-targeted ROCK inhibitor for the treatment of fibrostenotic Crohn's disease,
is currently in pre-IND stage, with Phase 1 clinical studies expected to
commence in 2023.

 

The Company has a strong track record of discovering new drug candidates
through its core strengths in medicinal chemistry and translational science,
enabling the Company to discover and develop differentiated therapeutics
against biologically or clinically validated targets. The Company's
accomplishments are evidenced not only by its two wholly-owned clinical-stage
product candidates and rapidly expanding preclinical pipeline, but also by its
strategic transactions, including the sale of pirtobrutinib (RXC005,
LOXO-305), a BTK inhibitor now in Phase 3 clinical development by Eli Lilly
following its acquisition of Loxo Oncology and RXC006, a Porcupine inhibitor
targeting fibrotic diseases including idiopathic pulmonary fibrosis (IPF),
which AstraZeneca is progressing in a Phase 1 clinical study. In addition,
Redx has forged collaborations with Jazz Pharmaceuticals.

 

To subscribe to Email Alerts from Redx, please visit:
www.redxpharma.com/investor-centre/email-alerts/
(http://www.redxpharma.com/investor-centre/email-alerts/)  

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCDZLFBLZLBBBK